Zilebesiran

Zilebesiran

Zilebesiran

Experimental drug

Zilebesiran is an experimental small interfering RNA developed by Roche and Alnylam that is administered subcutaneously twice annually to lower blood pressure in people already taking other antihypertensive drugs.[1][2][3] It works by impeding the synthesis of angiotensinogen in the liver.[4][5]

Quick Facts Clinical data, Other names ...

References

  1. [1]
    Carvalho, Thiago (2023). "RNA interference treatment targeting angiotensinogen lowers blood pressure". Nature Medicine. 29 (12): 2962–2963. doi:10.1038/d41591-023-00091-x. ISSN 1078-8956. PMID 37845541.
  2. [2]
    Khan, Rida S.; Frishman, William H. (22 February 2024). "Zilebesiran: A Promising Antihypertensive Therapy Inhibiting Angiotensinogen Synthesis". Cardiology in Review. doi:10.1097/CRD.0000000000000645. PMID 38385680.
  3. [3]
    Waldron, James (5 March 2024). "2nd win for Alnylam RNAi blood pressure med strengthens Roche's $2.8B biobucks bet". Fierce Biotech. Retrieved 6 March 2024.
  4. [4]
    Desai, Akshay S.; Webb, David J.; Taubel, Jorg; Casey, Sarah; Cheng, Yansong; Robbie, Gabriel J.; et al. (20 July 2023). "Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension" (PDF). New England Journal of Medicine. 389 (3): 228–238. doi:10.1056/NEJMoa2208391. hdl:20.500.11820/9ec1c393-058a-4fe7-8e8f-df207dcdfb85. PMID 37467498.
  5. [5]
    Bakris, George L.; Saxena, Manish; Gupta, Anil; Chalhoub, Fadi; Lee, Jongtae; Stiglitz, Daniel; et al. (5 March 2024). "RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial". JAMA. 331 (9): 740–749. doi:10.1001/jama.2024.0728. PMC 10873804. PMID 38363577.
Share this article:

This article uses material from the Wikipedia article Zilebesiran, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.